Form 4: Alnylam Director Margaret A. Hamburg Acquires Stock Options

Director Margaret A. Hamburg acquired 5,228 stock options in Alnylam Pharmaceuticals, Inc. on May 16, 2024.

Summary

• On May 16, 2024, Margaret A. Hamburg, a director of Alnylam Pharmaceuticals, Inc., acquired 5,228 stock options.
• The options have an exercise price of $151.22.
• These options vest in full on the earlier of the first anniversary of the grant date (May 16, 2025) or the date of retirement or resignation, provided such date occurs no more than 90 days prior to the first anniversary of the grant date.
• Following the transaction, Hamburg directly owns 5,228 derivative securities.

Sentiment

Score: 6

Explanation: The document is neutral in tone, simply reporting a transaction. The acquisition of stock options by a director is generally viewed as a mildly positive signal.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard transaction for directors of publicly traded companies, often used as part of their compensation package to align their interests with those of the shareholders.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the pharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Biogen also use stock options as part of their compensation packages for directors and officers.
• The vesting schedules and exercise prices are typically structured to incentivize long-term value creation.

Stakeholder Impact

• The acquisition of stock options by a director can positively influence shareholder sentiment, as it aligns the director's interests with those of the shareholders.

Key Dates